Key Summary Points {#FPar1}
==================

Cutaneous metastases of breast cancer (CMOBM) remain a therapeutic challenge.The oxygen flow assisted administration of topical methotrexate 5% (OFAMTX5%) achieved clinical and histological cure in a patient with superficial CMOBM, with no relapse for at least 6 months.OFAMTX5% represents a new treatment option for superficial CMOBM.

Introduction {#Sec1}
============

Cutaneous metastases occur in up to one-third of all patients with breast cancer and are usually a sign of poor prognosis \[[@CR1]\]. Cutaneous metastases of breast cancer (CMOBC) have a major impact on the quality of life of the patient and often represent difficult therapeutic challenges. Therapeutic options are systemic agents and/or skin-directed treatments. Radiotherapy \[[@CR2]\], surgical excision \[[@CR3]\] or electrochemotherapy \[[@CR4]\] are indicated for thicker skin metastases, either as monotherapy or adjuvant treatment. For thinner, more superficial skin metastases, topical treatments may be useful, such as imiquimod 5% cream \[[@CR3], [@CR5]--[@CR8]\], cryotherapy \[[@CR8]\], 5-fluorouracil 5% cream (5-FU) \[[@CR8]\], photodynamic therapy (PDT) \[[@CR9]--[@CR11]\] and applications of miltefosine 6% solution \[[@CR2], [@CR12], [@CR13]\]. All these treatments are either used as monotherapy or as adjuvant treatment.

Oxygen flow assisted topical administration of methotrexate 5% (OFAMTX, 5% methotrexate in a carrier solution) is a recently described technique that facilitates the permeation of the epidermis by medications, enabling penetration of the skin by high-molecular-weight molecules that normally do not do so \[[@CR14]\]. This technique has been found to have interesting treatment response rates for superficial basal cell carcinoma, mycosis fungoides and extramammary Paget's disease (EMPD), a chronically evolving and recurrent intraepidermal adenocarcinoma \[[@CR14]\]. As methotrexate is a chemotherapy drug used to treat certain breast cancers \[[@CR15]\], we have evaluated the efficacy of OFAMTX5% for treating superficial CMOBC. The patient provided written consent for publication of her clinical images and her case.

Case Report {#Sec2}
===========

A 51-year-old woman presented with an indurated mass of her right breast, suggesting a carcinomatous mastitis with axillary lymph node extension. Magnetic resonance imaging revealed a lesion affecting the entire right breast, 8 cm in size, with an infiltration of the nipple and the axillary lymph nodes. A biopsy of the breast lesion revealed an invasive ductal carcinoma, grade III by Bloom grading system, triple negative (estrogen receptor−, progesterone receptor− and HER-2−), with a high proliferation index (Ki67: 63%). Needle aspiration of axillary lymph nodes was also positive. Positron emission tomography (PET) and bone scintigraphy did not reveal distant metastasis. A neo-adjuvant chemotherapy was initiated with four courses of epirubicin and cyclophosphamide (75 mg/m^2^ and 500 mg/m^2^, respectively, every 15 days), followed by 12 once-weekly courses of paclitaxel (80 mg/m^2^). The overall clinical and biological tolerance was very good. One month later, a mastectomy and a sentinel lymph node biopsy were performed. Histological studies revealed multiple scattered lympho-vascular embolizations involving about 20% of the tumor mass. There was infiltration of two of the three lymph nodes, with micrometastases measuring 1.8- and 5-mm. Immunohistochemistry confirmed the triple negative character of the carcinoma. Histological staging was T1cN1cMx.

Two weeks following surgery, isolated macular and slightly infiltrated erythematous skin lesions were evidenced in the near vicinity of the mastectomy scar. A skin biopsy revealed a dermal infiltration with breast carcinoma cells, triple negative, with a Ki67 of 80%. Capecitabine chemotherapy (1250 mg/m^2^, twice-daily, 2 weeks every 3 weeks) was initiated and adjuvant radiotherapy was administered (50 Gy, 25 sessions of 2 Gy) to the right chest wall and the supraclavicular region, followed by a boost on the scar and skin metastases (16 Gy, 8 sessions of 2 Gy). Five months later, new cutaneous metastases appeared, presenting as Velpeau's nodules on the edge of the lower fields of the radiotherapy area (Fig. [1](#Fig1){ref-type="fig"}a). As the PET scanner did not reveal any internal and/or lymph node metastases, a skin-directed treatment with OFAMTX5% was applied (twice weekly for 2 weeks) to the lesions using the Dermadrop® device (MEDDROP GMBH, Hamburg, Germany) (Fig. [2](#Fig2){ref-type="fig"}a). The patient provided written informed consent for the off-label use of this technique (Eudract number 2017-000615-16).

In this procedure, a methotrexate 5% cartridge is inserted into the handpiece (Fig. [2](#Fig2){ref-type="fig"}b), following which the oxygen flow is started, projecting the methotrexate with the carrier solution through a fine needle onto the skin (Fig. [2](#Fig2){ref-type="fig"}c). The application continues for 5--10 min until a full saturation of the treated area is obtained, i.e. a yellowish liquid film remains on the skin (Fig. [2](#Fig2){ref-type="fig"}d). A plastic dressing is then applied for 24 h (Fig. [2](#Fig2){ref-type="fig"}e).

A biopsy performed just prior to the OFAMTX5% treatment revealed once again a superficial and deep dermal infiltration of neoplastic mammary cells (Fig. [1](#Fig1){ref-type="fig"}b) with cytokeratin-7 immunohistochemical expression (Fig. [1](#Fig1){ref-type="fig"}c). The treatment sessions were well tolerated and the patient did not experience any procedure-related discomfort during or after the sessions. Two months following the procedure, a post-inflammatory pigmentation was observed (Fig. [1](#Fig1){ref-type="fig"}d) but there was no clinical evidence of recurring infiltrated lesions. A control skin biopsy was performed and revealed a total remission (Fig. [1](#Fig1){ref-type="fig"}e). At the control visits 3 and 6 months after treatment, the post-inflammatory hyperpigmentation had faded and there was still no clinical evidence of a local recurrence of CMOBC.Fig. 1**a** Clinical aspect of breast cancer skin metastases before treatment, **b** histology image showing superficial tumoral infiltrate in the dermis, **c** immunohistochemistry image showing cytokeratin-7 positive tumor cells, **d** clinical aspect 2 months post-oxygen flow assisted topical administration of methotrexate 5% (OFAMTX; 5% methotrexate in a carrier solution) procedure, **e** control biopsy revealing no residual tumor nestsFig. 2**a** The Dermadrop^®^ device, **b** the handpiece containing a methotrexate 5% (yellow color) cartridge, **c** handpiece applying methotrexate in the carrier solution to the skin, **d** saturation point: the methotrexate solution is no longer absorbed by the skin, **e** the treated site is covered with a plastic film for 24 h

Discussion {#Sec3}
==========

This case demonstrates the possibility of treating superficial CMOBC with OFAMTX5% in a painless manner, while continuing chemotherapy. OFAMTX5% can be considered to be an alternative topical treatment option to other topical therapies, such as miltefosine \[[@CR2], [@CR12], [@CR13]\], imiquimod \[[@CR3], [@CR5]--[@CR7]\], 5-FU \[[@CR8]\] and methylaminolevulinate \[[@CR11]\] or aminolevulinate-PDT. These latter topical therapies are associated with grade 1--3 cutaneous toxicities, sometimes requiring dose tapering or treatment interruption. A major advantage of topical treatments is the general absence of systemic adverse events, with the exception of a flu-like syndrome observed in some patients receiving imiquimod. In addition, topical therapies are beneficial for treating superficial lesions regardless of the size due to their increased tolerability. Treatments are usually of long duration and recurrences are frequent; consequently, the tolerability of topical treatments is of utmost importance to maintain patient comfort and compliance with the treatment. Using topical treatments as adjuvant therapy with systemic agents likely increases the overall efficacy of the chosen treatment on cutaneous metastases. Combining topical therapies with different action mechanisms, i.e. immunostimulatory (imiquimod) and antimetabolic (methotrexate, 5-FU, miltefosine), probably further enhances effectiveness. However, it remains difficult to directly compare study results and adverse effect profiles due to the different action mechanisms, treatment durations, assessment methods, among others. A comparative overview of the topical treatment options for superficial breast cancer skin metastases is given in Table [1](#Tab1){ref-type="table"}.Table 1Topical treatment options for superficial breast cancer metastasesTreatment mechanismType of studyAdministration regimenNumber of patientsAssessmentAdverse eventsReferencesMitlefosine 6% solution AntimetaboliteOpen label2 drops/10 cm^2^1--2 treatment courses/day for 2--164 weeks (median 14 weeks)25Treatment-induced effect: 36% of the patients: 1 complete, 2 partial and 6 minor responses. Stable disease: 44%Progressive disease: 20%Cutaneous toxicities: Grade 1: 28%; Grade 3: 16%\[[@CR12]\]Double-blind, placebo-controlled2 drops/10 cm^2^1 treatment course/day for 1 week, then 2 treatment courses/day until treatment failure52Time to treatment failure: miltefosine arm, 56 days; placebo arm, 21 daysWell tolerated\[[@CR13]\]Imiquimod 5% cream Induces endogenous production of interferonCase report3--5 treatment courses/week, every 3 weeks with cryotherapy1Initial shrinking of the lesion\[[@CR8]\]Prospective5 treatment courses/weer for 8 weeks10Partial response: 20%Grade 1--2 transient local and systemic adverse effects\[[@CR5]\]Case report5 treatment courses/week for 8 weeks1Size reductionNo reported adverse effects\[[@CR3]\]Single-arm phase 24 days of treatment courses for 12 weeks, with paclitaxel treatment 100 mg/m^2^155 patients: complete response5 patients: partial responseOverall response rate: 72% (10/14)Cutaneous toxicities: Grades 1,2: 92%\[[@CR6]\]5-Fluorouracil 5% cream AntimetaboliteCase series2 treatment courses/dday (with cryotherapy) for 4 months2Good but transient clinical responsesAcceptable local adverse events\[[@CR8]\]Photodynamic therapy Induces selective apoptosisCase seriesIntravenous photofrin II-PDT375 complete, 13 partial and 19 non-respondersWell tolerated\[[@CR9]\]Case seriesTopical meso-tetra-porphon-PDT93 complete, 4 partial and 2 non-respondersNo adverse effects\[[@CR10]\]Case seriesMAL-PDT2Superficial clearing at 4 weeksPersistence of lesions in subcutisWell tolerated\[[@CR11]\]OFAMTX5% AntimetaboliteCase report2 treatment courses/week for 2 weeks1Complete histological response at 2 monthsNo recurrence at 6 monthsWell toleratedNo topical or systemic adverse effects\[[@CR14]\]*MAL* Methylaminolevulinate,*OFAMTX5%* 5% methotrexate in a carrier solution,*PDT* photodynamic therapy

In conclusion, OFAMTX5% is an effective and well-tolerated treatment for superficial CMOBC. More cases will have to be treated in order to determine optimal treatment regimens and its place in the armamentarium against CMOBC.
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